Methylphenidate Hydrochloride Tablet, Extended Release shortage
Methylphenidate Hydrochloride Tablet, Extended Release is currently listed in shortage by the FDA. The FDA lists 34 affected products. The reported reason: Demand increase for the drug; Other; Discontinuation of the manufacture of the drug. This page was last refreshed from FDA data on Oct 1, 2026.
Extended-release methylphenidate tablets have been in shortage for over a year, though all strengths currently have at least one supplier with available stock. Most manufacturers reporting the shortage still list supply, but some have delays stretching into late 2026.
Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers (see options) and your prescriber about a long-term plan.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Methylphenidate Hydrochloride Tablet, Extended Release. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 18, 2026Currently in shortage34 of 34 products affected.
-
Sep 17, 2026FDA refreshed this shortage record4 products updated.
-
Sep 16, 2026FDA refreshed this shortage record18 products updated.
-
Sep 15, 2026FDA refreshed this shortage record8 products updated.
-
Jul 26, 2023First reported to the FDA34 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Janssen Pharmaceuticals 📞 800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01) | — | Available | — | — |
| Current | Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01) | — | Available | — | — |
| Current | Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01) | — | Available | — | — |
| Current | Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01) | — | Available | — | — |
Manufacturer: Lannett Company, Inc. 📞 844-834-0530 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37) | — | Available | — | — |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37) | — | Limited Availability | Estimated recovery: November 2026 | Other |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37) | — | Available | — | — |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37) | — | Limited Availability | Estimated recovery: November 2026 | Other |
Manufacturer: Sun Pharmaceutical Industries, Inc. 📞 800-818-4555 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88) | — | Unavailable | Currently not marketed | Discontinuation of the manufacture of the drug |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88) | — | Unavailable | Currently not marketed | Discontinuation of the manufacture of the drug |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88) | — | Unavailable | Currently not marketed | Discontinuation of the manufacture of the drug |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88) | — | Unavailable | Currently not marketed | Discontinuation of the manufacture of the drug |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01) | — | Available | — | — |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01) | — | Available | — | — |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01) | — | Limited Availability | Estimated recovery: September 2026 | Other |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01) | — | Limited Availability | Estimated recovery: September 2026 | Other |
Manufacturer: Trigen Laboratories, LLC 📞 800-541-4802 7 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30) | — | Limited Availability | Allocation to current contracted customers | Demand increase for the drug |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10) | — | Limited Availability | Allocation to current contracted customers | Demand increase for the drug |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10) | — | Limited Availability | Allocation to current contracted customers | Demand increase for the drug |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10) | — | Limited Availability | Allocation to current contracted customers | Demand increase for the drug |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30) | — | Limited Availability | Allocation to current contracted customers | Demand increase for the drug |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10) | — | Limited Availability | Allocation to current contracted customers | Demand increase for the drug |
| Current | Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30) | — | Limited Availability | Allocation to current contracted customers | Demand increase for the drug |
Manufacturer: Vertical Pharmaceuticals, LLC 📞 800-541-4802 11 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30) | — | Available | — | — |
| Current | Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30) | — | Available | — | — |
| Current | Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30) | — | Available | — | — |
| Current | Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10) | — | Available | — | — |
| Current | Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10) | — | Available | — | — |
| Current | Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10) | — | Available | — | — |
| Current | Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30) | — | Available | — | — |
| Current | Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30) | — | Available | — | — |
| Current | Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10) | — | Available | — | — |
| Current | Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30) | — | Available | — | — |
| Current | Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30) | — | Available | — | — |
These rows are manufacturer reports to the FDA for Methylphenidate Hydrochloride Tablet, Extended Release — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Methylphenidate Hydrochloride Tablet, Extended Release? options further down this page.
Why is Methylphenidate Hydrochloride Tablet, Extended Release in shortage?
Extended-release methylphenidate is on the shortage list for a few different reasons depending on the manufacturer. Sun Pharmaceutical has permanently stopped making all of its strengths — 18 mg, 27 mg, 36 mg, and 54 mg — and those are currently not being sold at all. Lannett Company still has their 18 mg and 54 mg available, but their 27 mg and 36 mg are in short supply for an unspecified reason, with supply expected to recover around November 2026. Teva Pharmaceuticals has their 18 mg and 36 mg in limited supply (also for an unspecified reason) with an estimated recovery of September 2026, while their 27 mg and 54 mg remain available.
Trigen Laboratories has all of their strengths — 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg, and 72 mg — in limited supply simply because more people are needing this medication than usual, so they are currently only able to fill orders for their existing contracted customers. On the brighter side, both Vertical Pharmaceuticals (Relexxii, in 18 mg, 27 mg, 36 mg, 54 mg, and 72 mg) and Janssen Pharmaceuticals (Concerta, in 18 mg, 27 mg, 36 mg, and 54 mg) are reporting all of their products as fully available.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Methylphenidate Hydrochloride Tablet, Extended Release, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Methylphenidate Hydrochloride Tablet, Extended Release?
Your extended-release methylphenidate (the long-acting tablet) is currently listed on the FDA drug-shortage list. This is a widely used medicine, and the overall supply risk here is low, so I want to put this in perspective before anything else.
Every strength still has an available source right now. That includes the 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg, and 72 mg tablets — none of them have zero supply at this time. Whichever one you take, at least one manufacturer is still reporting it as available.
Here is how it looks: the shortage reflects higher demand for this medicine, one maker discontinuing its version, and other supply factors. Five of six manufacturers on this record are still reporting supply, and some limited strengths carry estimated recovery dates in September and November 2026. Because this is national, manufacturer-reported data, it may not match what your local pharmacy has on its shelf today.
What you can do:
- Keep taking your medicine exactly as prescribed — do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength; they can check wholesalers and other makers.
- If your pharmacy can't find your usual product, the same medicine may be available from another maker (such as SpecGx or Amneal), though it may not be in local stock.
- If your exact tablet can't be found, ask your prescriber or pharmacist about options, like combining strengths or a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
- This is a controlled substance. Transfers between pharmacies and switching strengths have extra federal/state rules — ask the pharmacy before you assume a transfer is possible.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Methylphenidate Hydrochloride Tablet, Extended Release?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Methylphenidate Hydrochloride Tablet, Extended Release is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Methylphenidate Hydrochloride | METHYLPHENIDATE HYDROCHLORIDE 5 mg/1 | Tablet · Oral | Amneal Pharmaceuticals of New York LLC | 00115-1800-01 |
| Methylphenidate Hydrochloride | METHYLPHENIDATE HYDROCHLORIDE 10 mg/1 | Tablet · Oral | Amneal Pharmaceuticals of New York LLC | 00115-1801-01 |
| Methylphenidate Hydrochloride | METHYLPHENIDATE HYDROCHLORIDE 20 mg/1 | Tablet · Oral | Amneal Pharmaceuticals of New York LLC | 00115-1802-01 |
| Methylphenidate Hydrochloride Extended-Release | METHYLPHENIDATE HYDROCHLORIDE 27 mg/1 | Tablet, Extended Release · Oral | SpecGx LLC | 00406-0127-01 |
| Methylphenidate Hydrochloride Extended-Release | METHYLPHENIDATE HYDROCHLORIDE 36 mg/1 | Tablet, Extended Release · Oral | SpecGx LLC | 00406-0136-01 |
| Methylphenidate Hydrochloride Extended-Release | METHYLPHENIDATE HYDROCHLORIDE 54 mg/1 | Tablet, Extended Release · Oral | SpecGx LLC | 00406-0154-01 |
| Methylphenidate Hydrochloride | METHYLPHENIDATE HYDROCHLORIDE 5 mg/1 | Tablet · Oral | SpecGx LLC | 00406-1142-01 |
| Methylphenidate Hydrochloride | METHYLPHENIDATE HYDROCHLORIDE 10 mg/1 | Tablet · Oral | SpecGx LLC | 00406-1144-01 |
| Methylphenidate Hydrochloride | METHYLPHENIDATE HYDROCHLORIDE 20 mg/1 | Tablet · Oral | SpecGx LLC | 00406-1146-01 |
| Methylphenidate Hydrochloride | METHYLPHENIDATE HYDROCHLORIDE 10 mg/1 | Tablet, Extended Release · Oral | SpecGx LLC | 00406-1445-01 |
| Methylphenidate Hydrochloride | METHYLPHENIDATE HYDROCHLORIDE 20 mg/1 | Tablet, Extended Release · Oral | SpecGx LLC | 00406-1473-01 |
| Methylphenidate Hydrochloride | METHYLPHENIDATE HYDROCHLORIDE 18 mg/1 | Tablet, Extended Release · Oral | Lannett Company, Inc. | 00527-3310-37 |
Alternative dosage forms of Methylphenidate Hydrochloride Tablet, Extended Release
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 30 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Methylphenidate Hydrochloride 18 mg | AvPAK | 1 tablet | $0.576 | AB | Discontinued |
| Methylphenidate Hydrochloride 18 mg | Trigen | 100 tablets | $0.576 | AB | Availability likely |
| Methylphenidate Hydrochloride 18 mg | Camber | 100 tablets | $0.576 | AB | Availability likely |
| Methylphenidate Hydrochloride 18 mg | American | 1 tablet | $0.576 | AB | Availability likely |
| Methylphenidate Hydrochloride 18 mg | Actavis | 100 tablets | $0.576 | AB | Availability likely |
| Methylphenidate Hydrochloride 18 mg | Lannett | 100 tablets | $0.576 | BX | Availability likely |
| Methylphenidate Hydrochloride 27 mg | AvPAK | 1 tablet | $0.645 | AB | Discontinued |
| Methylphenidate Hydrochloride 27 mg | Trigen | 100 tablets | $0.677 | AB | Availability likely |
| Methylphenidate Hydrochloride 27 mg | Camber | 100 tablets | $0.677 | AB | Availability likely |
| Methylphenidate Hydrochloride 27 mg | American | 1 tablet | $0.677 | AB | Availability likely |
| Methylphenidate Hydrochloride 27 mg | Actavis | 100 tablets | $0.677 | AB | Availability likely |
| Methylphenidate Hydrochloride 27 mg | Lannett | 100 tablets | $0.677 | BX | Availability likely |
| Methylphenidate Hydrochloride Extended-Release 27 mg | SpecGx | 100 tablets | $0.677 | — | Availability likely |
| Methylphenidate Hydrochloride 18 mg | Lannett | 100 tablets | $0.736 | AB | FDA listed |
| Methylphenidate Hydrochloride 18 mg | Sun | 100 tablets | $0.736 | — | Discontinued |
| Methylphenidate Hydrochloride 27 mg | Lannett | 100 tablets | $0.760 | AB | FDA listed |
| Methylphenidate Hydrochloride 27 mg | Sun | 100 tablets | $0.760 | — | Discontinued |
| Methylphenidate Hydrochloride 54 mg | Trigen | 100 tablets | $0.805 | AB | Availability likely |
| Methylphenidate Hydrochloride 54 mg | Camber | 100 tablets | $0.805 | AB | Availability likely |
| Methylphenidate Hydrochloride 54 mg | American | 1 tablet | $0.805 | AB | Availability likely |
| Methylphenidate Hydrochloride 54 mg | Actavis | 100 tablets | $0.805 | AB | Availability likely |
| Methylphenidate Hydrochloride 54 mg | Lannett | 100 tablets | $0.805 | BX | Availability likely |
| Methylphenidate Hydrochloride Extended-Release 54 mg | SpecGx | 100 tablets | $0.805 | — | Availability likely |
| Methylphenidate Hydrochloride 54 mg | Lannett | 100 tablets | $0.805 | AB | FDA listed |
| Methylphenidate Hydrochloride 54 mg | Sun | 100 tablets | $0.805 | — | Discontinued |
| Methylphenidate Hydrochloride 54 mg | AvPAK | 1 tablet | $0.809 | AB | Discontinued |
| Relexxii 18 mg | Vertical | 100 tablets | $10.945 | — | Availability likely |
| Relexxii 27 mg | Vertical | 100 tablets | $11.325 | — | Availability likely |
| Concerta 18 mg | Janssen | 100 tablets | $12.325 | AB | Availability likely |
| Concerta 27 mg | Janssen | 100 tablets | $12.654 | AB | Availability likely |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Methylphenidate Hydrochloride Tablet, Extended Release — that fall in the same broad treatment class (tx for attention deficit-hyperact(adhd)/narcolepsy) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other psychiatry shortages
Methylphenidate Hydrochloride Tablet, Extended Release shortage FAQs
Is Methylphenidate Hydrochloride Tablet, Extended Release in shortage?
Why is Methylphenidate Hydrochloride Tablet, Extended Release in shortage?
Which products are affected?
When will Methylphenidate Hydrochloride Tablet, Extended Release be available again?
Can I still get Methylphenidate Hydrochloride Tablet, Extended Release somewhere?
What should I do if I take Methylphenidate Hydrochloride Tablet, Extended Release?
Still have a question about the Methylphenidate Hydrochloride Tablet, Extended Release shortage?
Ask a pharmacist about this shortage →View Methylphenidate Hydrochloride Tablet, Ex... on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.